the placebo group in major acute cardiovascular events, as has recently been shown for cardiovascular outcome trials with the GLP-1 receptor agonists liraglutide (131), semaglutide (132), albiglutide (133) and dulaglutide 2 and the SGLT2 inhibitors empagliflozin (134) and canagliflozin (135)
Moreover, they provide effective body-weight control and may prevent the development of steroid-induced obesity (17)
Singaporean patients are encouraged to have a detailed discussion with their doctor to fully understand the risks and benefits of GLP-1 medications
In: Copel J, DAlton M, Feltovich H, et al., editors
Acute Kidney Injury: Gastrointestinal side effects of Zepbound like diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems if dehydration is severe